{
    "xml": "<topic id=\"PHP989\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/labetalol-hydrochloride\" basename=\"labetalol-hydrochloride\" title=\"LABETALOL HYDROCHLORIDE\">\n<title>LABETALOL HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_448\" namespace=\"/interactions/list-of-drug-interactions/beta-blockers/labetalol\">Labetalol</xref>\n</p>\n<data name=\"vtmid\">46547007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_613648210\" title=\"Beta-adrenoceptor blockers\">Beta-adrenoceptor blockers</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34515\" title=\"BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)\" namespace=\"/drug-classes/beta-adrenoceptor-blockers-systemic\">BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP52904\" outputclass=\"indicationsAndDose\" rev=\"1.33\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Controlled hypotension in anaesthesia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hypertension of pregnancy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 20&#8239;mg/hour, then increased if necessary to 40&#8239;mg/hour after 30&#8239;minutes, then increased if necessary to 80&#8239;mg/hour after 30&#8239;minutes, then increased if necessary to 160&#8239;mg/hour after 30&#8239;minutes, adjusted according to response; Usual maximum 160&#8239;mg/hour.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Use dose for hypertension.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hypertension following myocardial infarction</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8239;mg/hour, then increased to up to 120&#8239;mg/hour, dose to be increased gradually.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hypertensive emergencies</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg, to be given over at least 1 minute, then 50&#8239;mg every 5&#8239;minutes if required until a satisfactory response occurs; maximum 200&#8239;mg per course.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8239;mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50&#8211;200&#8239;mg.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hypertension</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 100&#8239;mg twice daily, dose to be increased at intervals of 14 days; usual dose 200&#8239;mg twice daily, increased if necessary up to 800&#8239;mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3&#8211;4 divided doses; maximum 2.4&#8239;g per day.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially 50&#8239;mg twice daily, dose to be increased at intervals of 14 days; usual dose 200&#8239;mg twice daily, increased if necessary up to 800&#8239;mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3&#8211;4 divided doses; maximum 2.4&#8239;g per day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg, dose to be given over at least 1 minute, then 50&#8239;mg after 5&#8239;minutes if required; maximum 200&#8239;mg per course.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8239;mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50&#8211;200&#8239;mg.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53008\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Liver damage</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52830\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Lichenoid rash</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Difficulty in micturition</ph>; <ph outputclass=\"sideEffect\">epigastric pain</ph>; <ph outputclass=\"sideEffect\">liver damage</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">postural hypotension</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">weakness</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52890\" outputclass=\"pregnancy\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>The use of labetalol in maternal hypertension is not known to be harmful, except possibly in the first trimester.</p>\n<p>If labetalol is used close to delivery, infants should be monitored for signs of alpha-blockade (as well as beta blockade).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53013\" outputclass=\"breastFeeding\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Infants should be monitored as there is a risk of possible toxicity due to alpha-blockade (in addition to beta-blockade).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52963\" outputclass=\"hepaticImpairment\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;severe hepatocellular injury reported.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52854\" outputclass=\"renalImpairment\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52789\" outputclass=\"monitoringRequirements\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">Liver damage</p>\n<p>Severe hepatocellular damage reported after both short-term and long-term treatment. Appropriate laboratory testing needed at first symptom of liver dysfunction and if laboratory evidence of damage (or if jaundice) labetalol should be stopped and not restarted.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP52759\" outputclass=\"effectOnLaboratoryTests\" rev=\"1.7\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Effect on laboratory tests</title>\n<body>\n<section>\n<sectiondiv>\n<p>Interferes with laboratory tests for catecholamines.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53019\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Avoid upright position during and for 3 hours after intravenous administration.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i>, give intermittently <i>in</i> Glucose 5% <i>or</i> Sodium chloride and glucose. Dilute to a concentration of 1&#8239;mg/mL; suggested volume 200&#8239;mL; adjust rate with in-line burette.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP989-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/labetalol-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74696\" title=\"Tablet\" namespace=\"/drugs/labetalol-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74704\" title=\"Solution for injection\" namespace=\"/drugs/labetalol-hydrochloride/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78099\" namespace=\"/treatment-summaries/hypertension\" title=\"Hypertension\" count=\"6\" rel=\"backlink\">Hypertension</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78218\" namespace=\"/treatment-summaries/beta-adrenoceptor-blocking-drugs\" title=\"Beta-adrenoceptor blocking drugs\" count=\"1\" rel=\"backlink\">Beta-adrenoceptor blocking drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_448\" namespace=\"/interactions/list-of-drug-interactions/beta-blockers/labetalol\" title=\"Labetalol\" count=\"1\" rel=\"link\">Labetalol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34515\" namespace=\"/drug-classes/beta-adrenoceptor-blockers-systemic\" title=\"BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)\" count=\"1\" rel=\"link\">BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74696\" namespace=\"/drugs/labetalol-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74704\" namespace=\"/drugs/labetalol-hydrochloride/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP989",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/labetalol-hydrochloride",
    "basename": "labetalol-hydrochloride",
    "title": "LABETALOL HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_448",
            "label": "Labetalol"
        }
    ],
    "vtmid": "46547007",
    "drugClassification": [
        "Beta-adrenoceptor blockers"
    ],
    "inheritsFromClass": [
        "BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Controlled hypotension in anaesthesia",
                        "html": "Controlled hypotension in anaesthesia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or intravenous injection"
                    ],
                    "textContent": "By intravenous infusion or by intravenous injection",
                    "html": "By intravenous infusion or by intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Hypertension of pregnancy",
                        "html": "Hypertension of pregnancy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 20 mg/hour, then increased if necessary to 40 mg/hour after 30 minutes, then increased if necessary to 80 mg/hour after 30 minutes, then increased if necessary to 160 mg/hour after 30 minutes, adjusted according to response; Usual maximum 160 mg/hour.",
                        "html": "<p>Initially 20&#8239;mg/hour, then increased if necessary to 40&#8239;mg/hour after 30&#8239;minutes, then increased if necessary to 80&#8239;mg/hour after 30&#8239;minutes, then increased if necessary to 160&#8239;mg/hour after 30&#8239;minutes, adjusted according to response; Usual maximum 160&#8239;mg/hour.</p>"
                    },
                    {
                        "textContent": "Use dose for hypertension.",
                        "html": "<p>Use dose for hypertension.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Hypertension following myocardial infarction",
                        "html": "Hypertension following myocardial infarction"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "15 mg/hour, then increased to up to 120 mg/hour, dose to be increased gradually.",
                        "html": "<p>15&#8239;mg/hour, then increased to up to 120&#8239;mg/hour, dose to be increased gradually.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Hypertensive emergencies",
                        "html": "Hypertensive emergencies"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "50 mg, to be given over at least 1 minute, then 50 mg every 5 minutes if required until a satisfactory response occurs; maximum 200 mg per course.",
                        "html": "<p>50&#8239;mg, to be given over at least 1 minute, then 50&#8239;mg every 5&#8239;minutes if required until a satisfactory response occurs; maximum 200&#8239;mg per course.</p>"
                    },
                    {
                        "textContent": "Initially 2 mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50&#8211;200 mg.",
                        "html": "<p>Initially 2&#8239;mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50&#8211;200&#8239;mg.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Hypertension",
                        "html": "Hypertension"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 100 mg twice daily, dose to be increased at intervals of 14 days; usual dose 200 mg twice daily, increased if necessary up to 800 mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3&#8211;4 divided doses; maximum 2.4 g per day.",
                        "html": "<p>Initially 100&#8239;mg twice daily, dose to be increased at intervals of 14 days; usual dose 200&#8239;mg twice daily, increased if necessary up to 800&#8239;mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3&#8211;4 divided doses; maximum 2.4&#8239;g per day.</p>"
                    },
                    {
                        "textContent": "Initially 50 mg twice daily, dose to be increased at intervals of 14 days; usual dose 200 mg twice daily, increased if necessary up to 800 mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3&#8211;4 divided doses; maximum 2.4 g per day.",
                        "html": "<p>Initially 50&#8239;mg twice daily, dose to be increased at intervals of 14 days; usual dose 200&#8239;mg twice daily, increased if necessary up to 800&#8239;mg daily in 2 divided doses, to be taken with food, higher doses to be given in 3&#8211;4 divided doses; maximum 2.4&#8239;g per day.</p>",
                        "ageGroup": "elderly"
                    },
                    {
                        "textContent": "50 mg, dose to be given over at least 1 minute, then 50 mg after 5 minutes if required; maximum 200 mg per course.",
                        "html": "<p>50&#8239;mg, dose to be given over at least 1 minute, then 50&#8239;mg after 5&#8239;minutes if required; maximum 200&#8239;mg per course.</p>"
                    },
                    {
                        "textContent": "Initially 2 mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50&#8211;200 mg.",
                        "html": "<p>Initially 2&#8239;mg/minute until a satisfactory response is achieved, then discontinue; usual dose 50&#8211;200&#8239;mg.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Liver damage",
                "html": "Liver damage"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Lichenoid rash",
                        "html": "Lichenoid rash",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Difficulty in micturition",
                        "html": "Difficulty in micturition",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "epigastric pain",
                        "html": "epigastric pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "liver damage",
                        "html": "liver damage",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "postural hypotension",
                        "html": "postural hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "weakness",
                        "html": "weakness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "The use of labetalol in maternal hypertension is not known to be harmful, except possibly in the first trimester.\n\nIf labetalol is used close to delivery, infants should be monitored for signs of alpha-blockade (as well as beta blockade).",
                "html": "<p>The use of labetalol in maternal hypertension is not known to be harmful, except possibly in the first trimester.</p><p>If labetalol is used close to delivery, infants should be monitored for signs of alpha-blockade (as well as beta blockade).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Infants should be monitored as there is a risk of possible toxicity due to alpha-blockade (in addition to beta-blockade).",
                "html": "<p>Infants should be monitored as there is a risk of possible toxicity due to alpha-blockade (in addition to beta-blockade).</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;severe hepatocellular injury reported.",
                "html": "<p>Avoid&#8212;severe hepatocellular injury reported.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required.",
                "html": "<p>Dose reduction may be required.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "Liver damage",
                "textContent": "Severe hepatocellular damage reported after both short-term and long-term treatment. Appropriate laboratory testing needed at first symptom of liver dysfunction and if laboratory evidence of damage (or if jaundice) labetalol should be stopped and not restarted.",
                "html": "<p>Severe hepatocellular damage reported after both short-term and long-term treatment. Appropriate laboratory testing needed at first symptom of liver dysfunction and if laboratory evidence of damage (or if jaundice) labetalol should be stopped and not restarted.</p>"
            }
        ]
    },
    "effectOnLaboratoryTests": {
        "effectOnLaboratoryTests": [
            {
                "type": "effectOnLaboratoryTests",
                "textContent": "Interferes with laboratory tests for catecholamines.",
                "html": "<p>Interferes with laboratory tests for catecholamines.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Avoid upright position during and for 3 hours after intravenous administration.",
                "html": "<p>Avoid upright position during and for 3 hours after intravenous administration.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride and glucose. Dilute to a concentration of 1 mg/mL; suggested volume 200 mL; adjust rate with in-line burette.",
                "html": "<p>For <i>intravenous infusion</i>, give intermittently <i>in</i> Glucose 5% <i>or</i> Sodium chloride and glucose. Dilute to a concentration of 1&#8239;mg/mL; suggested volume 200&#8239;mL; adjust rate with in-line burette.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74696",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74704",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78099",
                "label": "Hypertension",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78218",
                "label": "Beta-adrenoceptor blocking drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_448",
                "label": "Labetalol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34515",
                "label": "BETA-ADRENOCEPTOR BLOCKERS (SYSTEMIC)",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74696",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74704",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}